HUTCHMED (China) Limited (HCM)
NASDAQ: HCM · Real-Time Price · USD
14.21
+0.01 (0.07%)
Jan 21, 2025, 4:00 PM EST - Market closed
HUTCHMED (China) Revenue
HUTCHMED (China) had revenue of $305.68M in the half year ending June 30, 2024, with 51.29% growth. This brings the company's revenue in the last twelve months to $610.81M, down -19.34% year-over-year. In the year 2023, HUTCHMED (China) had annual revenue of $838.00M with 96.52% growth.
Revenue (ttm)
$610.81M
Revenue Growth
-19.34%
P/S Ratio
n/a
Revenue / Employee
$307,246
Employees
1,988
Market Cap
2.39B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 838.00M | 411.59M | 96.52% |
| Dec 31, 2022 | 426.41M | 70.28M | 19.73% |
| Dec 31, 2021 | 356.13M | 128.15M | 56.21% |
| Dec 31, 2020 | 227.98M | 23.09M | 11.27% |
| Dec 31, 2019 | 204.89M | -9.22M | -4.31% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 400.28B |
| Johnson & Johnson | 87.70B |
| Merck & Co. | 63.17B |
| AbbVie | 55.53B |
| AstraZeneca | 51.21B |
| Novartis AG | 49.94B |
| Thermo Fisher Scientific | 42.37B |
| Abbott Laboratories | 41.22B |
HCM News
- 8 days ago - HUTCHMED Announces NMPA Full Approval for ORPATHYS® (savolitinib) in China for Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC - GlobeNewsWire
- 19 days ago - Chinese Cancer Drug Developer Hutchmed Sharpens R&D Focus, Divests Non-Core JV For Over $600 Million - Benzinga
- 20 days ago - HUTCHMED Announces NDA Acceptance in China with Priority Review Status for ORPATHYS® and TAGRISSO® Combination in Lung Cancer Patients with MET amplification After Progression on First-Line EGFR Inhibitor Therapy - GlobeNewsWire
- 20 days ago - Billionaire Li Ka-shing's Hutchmed in $608 mln health unit stake sales - Reuters
- 20 days ago - HUTCHMED Announces US$608 million Divestment of Non-Core Joint Venture - GlobeNewsWire
- 5 weeks ago - HUTCHMED to Receive Milestone Payment from Takeda following First European Reimbursement for FRUZAQLA® (fruquintinib) - GlobeNewsWire
- 5 weeks ago - HUTCHMED Announces Breakthrough Therapy Designation in China for ORPATHYS® and TAGRISSO® Combination in Certain Lung Cancer Patients After Disease Progression on EGFR Inhibitor Therapy - GlobeNewsWire
- 7 weeks ago - Innovent and HUTCHMED Jointly Announce NMPA Conditional Approval for TYVYT® (Sintilimab Injection) in Combination with ELUNATE® (Fruquintinib) for the Treatment of Advanced Endometrial Cancer - PRNewsWire